Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 427

1.

The status of poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors in ovarian cancer, part 1: olaparib.

Miller RE, Ledermann JA.

Clin Adv Hematol Oncol. 2016 Aug;14(8):619-27. Review.

PMID:
27487106
2.

Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancer.

Ivy SP, Liu JF, Lee JM, Matulonis UA, Kohn EC.

Expert Opin Investig Drugs. 2016;25(5):597-611. doi: 10.1517/13543784.2016.1156857. Epub 2016 Mar 16. Review.

PMID:
26899229
4.

Olaparib: an oral PARP-1 and PARP-2 inhibitor with promising activity in ovarian cancer.

Gunderson CC, Moore KN.

Future Oncol. 2015;11(5):747-57. doi: 10.2217/fon.14.313. Review.

PMID:
25757679
5.

Development of Olaparib for BRCA-Deficient Recurrent Epithelial Ovarian Cancer.

Tewari KS, Eskander RN, Monk BJ.

Clin Cancer Res. 2015 Sep 1;21(17):3829-35. doi: 10.1158/1078-0432.CCR-15-0088. Epub 2015 Jul 13. Review.

6.

Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.

Parkes EE, Kennedy RD.

Oncologist. 2016 May;21(5):586-93. doi: 10.1634/theoncologist.2015-0438. Epub 2016 Mar 28. Review.

7.

The safety and efficacy of olaparib therapy in patients with relapsed ovarian cancer.

Nirsimloo R, Gourley C.

Expert Rev Anticancer Ther. 2016 Jun;16(6):597-603. doi: 10.1080/14737140.2016.1182429. Review.

PMID:
27115428
8.

[Abnormalities of DNA repair and gynecological cancers].

Auguste A, Leary A.

Bull Cancer. 2017 Nov;104(11):971-980. doi: 10.1016/j.bulcan.2017.09.007. Epub 2017 Oct 18. Review. French.

PMID:
29054544
9.

Olaparib for the treatment of epithelial ovarian cancer.

McLachlan J, Banerjee S.

Expert Opin Pharmacother. 2016;17(7):995-1003. doi: 10.1517/14656566.2016.1165205. Epub 2016 Apr 4. Review.

PMID:
26967466
10.

The current status of PARP inhibitors in ovarian cancer.

McLachlan J, George A, Banerjee S.

Tumori. 2016 Oct 13;102(5):433-440. doi: 10.5301/tj.5000558. Epub 2016 Sep 24. Review.

PMID:
27716873
11.

Advances in PARP inhibitors for the treatment of breast cancer.

Dizdar O, Arslan C, Altundag K.

Expert Opin Pharmacother. 2015;16(18):2751-8. doi: 10.1517/14656566.2015.1100168. Epub 2015 Oct 20. Review.

PMID:
26485111
12.

Olaparib for the treatment of ovarian cancer.

Bornstein E, Jimeno A.

Drugs Today (Barc). 2016 Jan;52(1):17-28. doi: 10.1358/dot.2016.52.1.2440714. Review.

PMID:
26937492
13.

The promising PARP inhibitors in ovarian cancer therapy: From Olaparib to others.

Chen Y, Du H.

Biomed Pharmacother. 2018 Mar;99:552-560. doi: 10.1016/j.biopha.2018.01.094. Epub 2018 Feb 20. Review.

PMID:
29895102
14.

Homologous recombination deficiency and ovarian cancer.

Ledermann JA, Drew Y, Kristeleit RS.

Eur J Cancer. 2016 Jun;60:49-58. doi: 10.1016/j.ejca.2016.03.005. Epub 2016 Apr 9. Review.

PMID:
27065456
15.

[From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].

Schreiber V, Illuzzi G, Héberlé E, Dantzer F.

Bull Cancer. 2015 Oct;102(10):863-73. doi: 10.1016/j.bulcan.2015.07.012. Epub 2015 Sep 15. Review. French.

PMID:
26384693
16.

Spotlight on olaparib in the treatment of BRCA-mutated ovarian cancer: design, development and place in therapy.

Lorusso D, Tripodi E, Maltese G, Lepori S, Sabatucci I, Bogani G, Raspagliesi F.

Drug Des Devel Ther. 2018 May 29;12:1501-1509. doi: 10.2147/DDDT.S124447. eCollection 2018. Review.

17.

Patient Counseling and Management of Symptoms During Olaparib Therapy for Recurrent Ovarian Cancer.

Moore KN, Monk BJ.

Oncologist. 2016 Aug;21(8):954-63. doi: 10.1634/theoncologist.2015-0268. Epub 2016 Jun 2. Review.

18.

Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer.

Rafii S, Gourley C, Kumar R, Geuna E, Ern Ang J, Rye T, Chen LM, Shapira-Frommer R, Friedlander M, Matulonis U, De Greve J, Oza AM, Banerjee S, Molife LR, Gore ME, Kaye SB, Yap TA.

Oncotarget. 2017 Jul 18;8(29):47154-47160. doi: 10.18632/oncotarget.17005.

19.

New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.

Liu FW, Tewari KS.

Curr Treat Options Oncol. 2016 Mar;17(3):12. doi: 10.1007/s11864-015-0378-9. Review.

20.

Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition.

Lheureux S, Bruce JP, Burnier JV, Karakasis K, Shaw PA, Clarke BA, Yang SY, Quevedo R, Li T, Dowar M, Bowering V, Pugh TJ, Oza AM.

J Clin Oncol. 2017 Apr 10;35(11):1240-1249. doi: 10.1200/JCO.2016.71.3677. Epub 2017 Feb 21.

PMID:
28221868

Supplemental Content

Support Center